Spelling suggestions: "subject:"fistula"" "subject:"vistula""
31 |
Women's perceptions and experiences of post-operative physiotherapy management at an Obstetric Fistula Center in Eldoret, KenyaMuia, Catherine Mwikali January 2017 (has links)
Masters of Science - Msc (Physiotherapy) / Post-operative physiotherapy plays a vital role in the management of patients with
incontinence in order to optimise the outcome of obstetric fistula surgery. Women who
suffer residual urinary incontinence continue to experience shame, social isolation and
institutional rejection. Incontinence continues to impair them leading to lower levels of role
participation and restriction in most activities. Gynocare Fistula Center, Eldoret, receives a
number of referrals for women with obstetric fistula requiring surgical and physiotherapy
care. Many studies have focused on the determinants of surgical outcomes and social reintegration
but none have focused on woman's perceptions and experiences with postoperative
physiotherapy. While continence is not always achieved immediately after
surgery, this study was designed to explore women's perceptions and experience of postoperative
physiotherapy management at an obstetric fistula center in Eldoret,Kenya.
Participants were then asked about their experiences and related perceptions and perceived
challenges regarding the physiotherapy service following discharge from the Center. An
explorative qualitative method was used to explore the women's perceptions and
experiences of the post-operative physiotherapy management, as well as their perceived
challenges regarding access to physiotherapy post discharge.
|
32 |
Avaliação das variáveis associadas à patência de fístulas arteriovenosas para hemodiálise confeccionadas pelo nefrologistaRodrigues, Anderson Tavares 20 March 2015 (has links)
Submitted by Renata Lopes (renatasil82@gmail.com) on 2017-06-19T11:21:12Z
No. of bitstreams: 1
andersontavaresrodrigues.pdf: 12102128 bytes, checksum: ad04f5fdd01e1041a5459207d8137ad5 (MD5) / Approved for entry into archive by Adriana Oliveira (adriana.oliveira@ufjf.edu.br) on 2017-06-29T12:18:45Z (GMT) No. of bitstreams: 1
andersontavaresrodrigues.pdf: 12102128 bytes, checksum: ad04f5fdd01e1041a5459207d8137ad5 (MD5) / Made available in DSpace on 2017-06-29T12:18:45Z (GMT). No. of bitstreams: 1
andersontavaresrodrigues.pdf: 12102128 bytes, checksum: ad04f5fdd01e1041a5459207d8137ad5 (MD5)
Previous issue date: 2015-03-20 / A doença renal crônica (DRC) é uma enfermidade de grande
morbimortalidade. A hemodiálise periódica é o método mais amplamente utilizado na
manutenção da sobrevida dos pacientes com DRC. No tratamento hemodialítico é
necessário uma via de um acesso vascular, sendo o padrão-ouro é a fístula
arteriovenosa (FAV). As principais complicações da FAV são a falência do acesso e
consequente maior morbimortalidade. Os objetivos do trabalho são: 1) avaliar a taxa
de sucesso nas FAV confeccionadas pelo nefrologista; e 2) identificar as variáveis clínicas, laboratoriais e demográficas que impactam na patência da FAV. Método: Estudo de coorte retrospectiva caracterizado pelo exame de prontuários de
pacientes com DRC e que realizaram confecção de FAV pelo nefrologista. Foram
incluídos os prontuários de 101 pacientes, totalizando 159 procedimentos entre junho de 2010 e junho de 2013. Resultados: Das FAV realizadas, 124 (78%) apresentaram patência imediata e 110 (62,9%) apresentaram patência tardia. Das
variáveis estudadas somente a hemoglobina mostrou relação com a patência tardia
da FAV (p=0,05). Pressão arterial elevada no momento da cirurgia se associou com redução do número de procedimentos por paciente com p=0,001. FAV distais se associaram a maior número de procedimentos por paciente com p=0,03.
Adicionalmente, observou-se que o nosso índice de sucesso de patência da FAV
apresentou índices compatíveis com os da literatura por outros nefrologistas e cirurgiões vasculares. Conclusão: Manutenção de hemoglobina nas faixas recomendadas impactam favoravelmente na patência tardia da FAV, pressão arterial
elevada no momento da cirurgia associou-se com menor número de procedimentos
a que o paciente é submetido. Os procedimentos distais se associaram a maior
número de procedimentos por paciente, enquanto os proximais são mais frequentes
em pacientes com 2 acessos, indicando sua utilização principalmente na falha dos
acessos distais. / Chronic kidney disease (CKD) is an illness of high morbidity and mortality.
The periodic hemodialysis is the most widely used method in maintaining the survival
of patients with CKD. In hemodialysis is needed a vascular access, and the gold
standard is the arteriovenous fistula (AVF). The main complications of AVF are the
failure of access and consequent higher mortality. The objectives are: 1) to evaluate
the success rate in AVF made by a nephrologist; and 2) to identify clinical, laboratory
and demographic variables that impact the AVF patency. Method: Retrospective
cohort study characterized the examination records of patients with CKD who
underwent construction of AVF by a nephrologist. The medical records of 101
patients were included, totaling 159 procedures between June 2010 and June 2013.
Results: Of AVF performed, 124 (78%) had immediate patency and 110 (62.9%) had
late patency. Of the variables studied only hemoglobin was related to the late patency
of AVF (p = 0.05). High blood pressure at the time of surgery was associated with
fewer procedures per patient with p = 0.001. Distal AVF associated with a major
number of procedures per patient with p = 0.03. Additionally, it was observed that our
AVF patency success rate compatible with the indexes presented in the literature by
other nephrologists and vascular surgeons. Conclusion: hemoglobin maintenance at
the recommended tracks impact favorably on late patency of the AVF, high blood
pressure at the time of surgery was associated with fewer procedures which the
patient is submitted. The distal procedures associated with a major number of
procedures per patient, while the proximal are more frequent in patients with 2
accesses, indicating its use mainly in the failure of distal access.
|
33 |
Diagnosis, treatment and prophylaxis of pancreatic fistulas in severe necrotizing pancreatitis and the long-term outcome of acute pancreatitisKarjula, H. (Heikki) 03 December 2019 (has links)
Abstract
Acute infected necrotizing pancreatitis (ANP) is a very complex disease with a high risk of complications and death. ANP is difficult to treat and is often associated with poor outcomes. Despite the increasing data on the technical details required to perform a mini-invasive necrosectomy for walled-off necrosis (WON), relatively few studies have focused on the presence and consequences of pancreatic duct disruption in the context of APN. Moreover, the long-term prognosis of patients with acute pancreatitis (AP) is scant.
The aim of this study was to examine the diagnosis, treatment and prophylaxis of pancreatic fistulas (PFs) associated with APN. In addition, the long-term prognosis of AP was evaluated.
The study population consists of the patients with AP treated at Oulu University Hospital, Finland (Studies I–IV) and Copenhagen University Hospital, Denmark (Study II) during 1995–2015.
In the first part of the study, all consecutive patients following open necrosectomy for infected ANP were demonstrated to have PF. Endoscopic transpapillary pancreatic stenting (ETPS) was attempted and proven to be an effective and safe treatment for patients with PF.
In Study II, prophylactic pancreatic stenting in the early stage of the disease was tested in a randomized controlled trial to the patients with ANP to prevent PFs associated with the disease. However, the study showed that the patients with ANP did not benefit from early prophylactic pancreatic ductal stenting (PPDS); instead, it seemed to be harmful for the patients.
The results of Study III showed that single drain amylase level measurement after surgical necrosectomy is unreliable. According to this study, serial measurements are recommended to diagnose PFs after necrosectomy.
Study IV including 1644 patients showed that AP, especially alcohol AP, was associated with a high long-term mortality. On the other hand, AP without an alcohol aetiology had a minimal impact on survival.
In conclusion, in patients with infected ANP, a PF has to be considered in treatment, but the prevention of ductal leak with PPDS is not recommended. In addition, the poor long-term outcome among alcohol AP patients was due to alcohol-related diseases. / Tiivistelmä
Akuutti nekrotisoiva haimatulehdus ja erityisesti siihen liittyvä bakteeri-infektio on sairaus, johon liittyy korkea komplikaatio- ja kuolleisuusriski. Tautia usein komplisoi infektion lisäksi nekroosiin liittyvä haimafisteli, joka tekee hoidosta entistä haasteellisemman. Viime aikaisissa tutkimuksissa on käsitelty runsaasti mini-invasiivista nekrosektomiaa, mutta suhteellisen vähän on tutkimuksia nekrotisoivaan haimatulehdukseen liittyvästä fisteliongelmasta. Haimatulehdus-potilaiden pitkäaikaisennuste on myös epäselvä.
Tämän väitöskirjatutkimuksen tavoitteena oli selvittää nekrotisoivaan haimatulehdukseen liittyvän haimafistelin yleisyyttä, diagnostiikkaa, ehkäisyä ja hoitoa. Lisäksi tarkasteltiin akuuttiin haimatulehdukseen sairastuneiden potilaiden pitkäaikaisennustetta.
Ensimmäisessä osatyössä ilmeni, että kaikille potilaille, joille suoritettiin haiman nekrosektomia kehittyi fisteli ja endoskooppinen transpapillaarinen haimateiden stenttaus (ETPS) osoittautui hyväksi ja turvalliseksi hoidoksi fistelin hoidossa.
Toisessa prospektiivisessa randomoidussa kontrolloidussa osatyössä tutkittiin profylaktista haimateiden stenttausta nekrotisoivassa haimatulehduksessa. Tutkimus osoitti, etteivät potilaat hyötyneet stenttauksesta: toimenpiteestä oli enemmän haittaa kuin hyötyä. Tämän tutkimuksen mukaan protetisointia ei suositella tehtäväksi taudin alkuvaiheessa.
Kolmannessa osatyössä selvitettiin haiman nekrosektomian jälkeisen haimafistelin diagnosointia. Tutkimustuloksen mukaan haimafistelin osoittamiseksi dreenieritteen amylaasitasoa mittaamalla tarvitaan useita mittauskertoja, koska yksittäisen mittauksen sensitiivisyys on matala.
Neljännessä osatyössä analysoitiin Oulun yliopistollisessa sairaalassa 1995–2012 akuutin haimatulehduksen sairastaneiden työikäisten potilaiden pitkäaikaisennustetta ja kuolinsyitä. Noin kymmenen vuoden seurannassa tutkimusryhmän (n = 1 644) kuolleisuus oli yli nelinkertainen verrattuna ikä- ja sukupuolivakioituihin verrokeihin (n = 8 220). Merkittävin kuolleisuutta lisäävä tekijä oli alkoholi.
Tutkimuksemme osoitti, että infektoituneen haimanekroosiin liittyvä haimafisteli on huomioitava hoidossa. Varhaisesta profylaktisesta haimateiden protetisoinnista ei tutkimuksessa osoitettu olevan hyötyä. Alkoholin aiheuttaman haimatulehduksen pitkäaikaisennusteen mortaliteetti on korkea johtuen alkoholin käytöstä ja siihen liittyvistä sairauksista.
|
34 |
Uticaj različitih antitromboznih lekova na prevenciju nastanka rane tromboze arteriovenskih fistula za hemodijalizu kod bolesnika sa terminalnom bubrežnom insuficijencijom / The use of different antithrombotic drugs for the prevention of early thrombosis of arteriovenous fistula for hemodialysis in patients with end stage renal diseaseFilipov Predrag 21 April 2017 (has links)
<p>UVOD: Komplikacije terminalne bubrežne isuficijencije (TBI) kada se jačina glomerularne filtracije (JGF) smanji ispod 10 mL/min moguće je lečiti jedino hroničnom dijalizom ili transplantacijom bubrega tj. nadoknadom potpuno ili delimično izgubljene bubrežne funkcije. Uz blagovremenu edukaciju bolesnika o progresivnom toku hronične bubrežne bolesti, mogućnostima dijaliznog tretmana i transplantacije bubrega, treba na vreme obezbediti stalni funkcionalni vaskularni pristup za hemodijalizu (HD) hirurškom intervencijom kreiranja arteriovenske fistule (AVF), po mogućnosti najmanje 6 meseci pre anticipiranog započinjanja HD, jer je za njenu maturaciju potrebno 4 do 6 nedelja. Primarna AVF je opštepreporučeni najbolji stalni vaskularni pristup za bolesnike kod kojih se planira hemodijaliza. Najčešći razlog za disfunkciju vaskularnog pristupa za hemodijalizu su u 80% slučajeva trombozne komplikacije, koje se u 90% slučajeva javljaju na venskom segmentu AVF i posledica su progresivne venske neointimalne hiperplazije. Pored histoloških karakteristika zida venskog krvnog suda i hemodinamskih uslova, u etiopatogenezi ovog »adaptivnog odgovora« vrlo značajnu ulogu igraju endotel i ostale komponente hemostaznog sistema (trombocitna, koagulaciona i fibrinolizna), imunološki i citološki činioci i genetski faktori. Prevencija nastanka rane tromboze vaskularnog pristupa za hemodijalizu kod bolesnika sa TBI je moguća primenom antitromboznih lekova, tj. antitrombocitne ili antikoagulantne terapije. CILJ: Proceniti efikasnost primenjenih antitromboznih lekova (tiklopidina i nadroparin-kalcijuma) u prevenciji nastanka rane tromboze/afunkcionalnosti AVF za hemodijalizu za vreme njene maturacije unutar 6 nedelja od kreiranja u bolesnika sa TBI. Ispitati nivo biomarkera hemostaznog sistema i markere trombofilije u bolesnika sa TBI pre kreiranja AVF u cilju dopune uzroka nastanka rane tromboze/afunkcionalnosti arteriovenskih fistula za hemodijalizu. Ispitati učestalost trombofilije i njen uticaj na funkcionalnost AVF i uporediti efikasnost primenjenih preventivnih režima između bolesnika sa i bez trombofilije. MATERIJAL I METODE: U ispitivanje su uključene osobe oba pola sa prethodno postavljenom dijagnozom TBI kod kojih nisu postojale kontraindikacije za planirno hirurško kreiranje prvog stalnog vaskularnog pristupa za hemodijalizu u vidu autologne arteriovenske fistule (AAVF). Nakon hirurškog kreiranja radiocefalične arteriovenske fisule u distalnoj trećini podlaktice nedominantne ruke (89/121), intermedijalne (4/121) ili proksimalne (28/121) AAVF u studiju je uključen 121 ispitanik, koji su u cilju procene uticaja različitih antitromboznih lekova na sprečavanje nastanka rane tromboze fistula za hemodijalizu kod bolesnika sa TBI ispitanici su podeljeni u 3 grupe: Grupa I, kontrolna; 40 ispitanika koji nakon kreiranja AVF nisu dobijali antitromboznu terapiju, Grupa II; 42 ispitanika kod kojih je dan nakon kreiranja AVF započeta primena antitrombocitnog leka iz grupe tienopiridina, Ticlodix® (ticlopidin) tbl a 250 mg, 2 x ½ tbl dnevno tokom 6 nedelja i Grupa III; 39 ispitanika kod kojih je dan nakon kreiranja AVF započeta subkutana primena antikoagulantnog leka iz grupe niskomolekularnih heparina, Fraxiparine® (nadroparin-kalcijum) 2850 anti Xa i.j. (0.3 ml) dnevno tokom 6 nedelja. Jednokratno određivanje laboratorijskih parametara pokazatelja bubrežne funkcije, metabolizma glukoze i hroničnog zapaljenja, funkcionalnosti hemostaznog sistema, trombofilnih markera i genskog polimorfizma vršeno je unutar dve nedelje pre hirurškog kreiranja AAVF. Kriterijum za utvrđivanje ishoda uticaja antitrombozne terpije predstavlja maturacija AVF koja je definisana kao uspešna ako je započeto sprovođenje efikasne hemodijalize najranije 6 nedelja nakon njenog hirurškog kreiranja po proceni nadležnog nefrologa. Dijagnoza prisustva tromboze AVF postavljena je od strane nadležnog vaskularnog hirurga/nefrologa fizikalnim pregledom tokom njene maturacije, koji je podrazumevao inspekciju, palpatorno utvrđivanje odsustva karakterističnog trila i auskultatornih karakteristika protočnosti AVF ili ultarsonografskim pregledom od strane radiologa. REZULTATI: Između ispitivanih grupa u odnosu na broj tromboziranih/ afunkcionalnih AVF tokom njene maturacije (12/40 vs. 4/42 vs. 5/39; P=0.033), ustanovljena je značajna statistička razlika kao i poređenjem broja tromboziranih/afunkcionalnih AVF tokom sazrevanja u kontrolnoj grupi u odnosu na grupu ispitanika (objedinjene Grupe II i Grupa III) koja je primala antitromboznu profilaksu (12/40 vs. 9/81; P=0.009). Daljom analizom ispitivanih grupa, utvrđena je statistički značajna razlika u broju tromboziranih/afunkcionih AV fistula između kontrolne Grupe I i Grupe II (P=0.019). Testiranjem razlike u broju tromboziranih/ afunkcionalnih AVF između ispitanika kontrolne Grupe I i Grupe III nije dobijena statistički značajna razlika, kao ni između Grupe II i Grupe III. Zastupljenost broja tromboziranih/afunkcionalnih distalnih AVF za vreme njihove maturacije (12/33 vs 2/31 vs. 3/24; P=0.008) se između ispitivanih grupa značajno statistički razlikovala kao i zastupljenost tromboziranih/afunkcionalnih distalnih AVF tokom sazrevanja u kontrolnoj grupi u odnosu na grupu ispitanika koja je primala antitromboznu profilaksu (12/34 vs. 5/55; P=0.002). Testiranjem statističke razlike u broju tromboziranih/afunkcionalnih distalnih AVF između ispitanika kontrolne Grupe I i Grupe II utvrđena je statistički značajna razlika (P=0.005), dok između Grupe I i Grupe III (P=0.051), kao ni između Grupe II i Grupe III (P=0.439) nije dobijena statistički značajna razlika. Između podgrupa ispitanika kod kojih je došlo do tromboze/afunkcionalnosti AVF 21/121 (17.35%) i podgrupe ispitanika sa funkcionalno maturiranom AVF 90/121 (82.64%), značajna statistička razlika ispitanih hemostaznih parametara je bila prisutna u vrednostima agregabilnosti trombocita uz kolagen kao induktor (59.33±33.1 vs. 75.04±29.6; P=0.033). Značajna statistička razlika je zabeležena i u zastupljenosti sledećih trombofilnih markera: deficita PC (3/21 vs. 3/100; P=0.030), APC-R (4/21 vs. 5/100; P=0.026), prisustva antifosfolipidnih ACL IgM antitela (1/21 vs. 0/100; P=0.028), heterozigotnog polimorfizma FV G1691A (3/21 vs. 3/100; P=0.03) i homozigotne mutacije gena FII G20210A (1/21 vs. 0/100; P=0.028), između podgrupa bolesnika sa tromboziranom afunkcionalnom i funkcionalnom AVF. Takođe je značajna statistička razlika između podgrupa bolesnika kod kojih je došlo tromboze/afunkcionalnosti AVF i podgrupe ispitanika sa funkcionalno maturiranom AVF bila prisutna u odnosu na postojanje ranijih tromboza (23/21 vs 19/100; P=0.000) kao i zastupljenosti izolovanih venskih tromboza (9/21 vs. 2/100; P=0.000). Prediktivni potencijal pojedinačnih parametara za maturaciju AVF ispitan je univarijantnom logističkom regresionom analizom. Prilikom ispitivanja uticaja pojedinačnih parametara na maturaciju fistule, zapazili smo da su ispitanici koji su primali antitromboznu terapiju imali 3 puta veću šansu za funkcionalno maturiranu AVF [OR 3.45 (1.3-9.03)] u odnosu na bolesnike bez terapije. Ispitanici koji su imali prethodne tromboze su imali višestruko povišen rizik [OR 6.92 (2.51-19.06)] za nastanak tromboze/afunkcionalnost AVF tokom maturacije. Prilikom ispitivanja uticaja pojedinačnih parametara na rizik od pojave tromboze/afunkcionalnosti distalne AVF, zapažamo da primena antitrombozne terapije [OR 5.4 (CI 1.7 - 17.35)] petostruko snižava rizik za nastanak tromboze/ afunkcionalnosti distalne AVF, odnosno da primena antitrombozne terapije petostruko povećava šansu za adekvatnu maturaciju distalne AVF. Ispitanici koji su imali aterosklerotske KVB [OR 0.32 (0.1-0.98)] i ranije tromboze [OR 0.14 (0.04-0.44)] su imali za 68% i 86% manju verovatnoću za adekvatnu maturaciju distalne AVF (334). Trombofilija je bila prisutna u 59/121 (48.8%) ispitanika. U odnosu na markere aktivacije koagulacione komponente hemostaznog sistema i inflamatorne pokazatelje, između podgrupa ispitanika sa ili bez trombofilije statistički značajna razlika je bila prisutna u vrednostima koncentracije FVIII (170.35±103.97 vs. 235.26±124.80; P=0.02) i odnosa trombociti/limfociti (181±64.58 vs. 148.11±66.15; P=0.026). U odnosu na lokalizaciju AVF, u podgrupi ispitanika sa trombofilijom i tromboziranom/ afunkcionalnom AVF, njih 8/11 su pripadale distalnim AVF, 3/11 proksimalnim AVF, dok je u podgrupi ispitanika bez trombofilije i tromboziranom/afunkcionalnom AVF, njih 9/10 imalo distalnu, a 1/10 proksimalnu AVF. U grupi bolesnika sa trombofilijom nije zabeleženo prisustvo statistički značajne razlike u efikasnosti primenjenih antitromboznih režima merene učestalošću tromboza/afunkcionalnosti AVF u odnosu na bolesnike sa trombofilijom koji nisu primali antitromboznu terapiju (5/19 vs. 2/18 vs. 4/22; P=0.493). U grupi ispitanika bez trombofilije utvrđeno je postojanje statistički značajne razlike u učestalosti tromboza/afunkcionalnosti AVF između grupe sa i bez primene antitromboznih lekova kako u ukupnom broju tromboziranih/afunkcionalnih AVF (7/21 vs. 2/24 vs. 1/17; P=0.030). Iako je zastupljenost tromboza/afunkcionalnosti AVF u bolesnika sa kombinovanom trombofilijom češća u odnosu na ispitanike koji su imali drugu vrstu ili uopšte nisu imali trombofiliju (6/18 vs. 15/103; P=0.052), ona nije dostigla statistički značajnu vrednost. ZAKLJUČAK: Profilaktička primena antitromboznih lekova (tiklopidina i nadroparin-kalcijuma) smanjuje učestalost pojave rane tromboze i pojavu primarne nefunkcionalnosti AVF za hemodijalizu tokom njene maturacije. Primena antitrombozne terapije petostruko snižava rizik za nastanak tromboze/ afunkcionalnosti distalne AVF tokom njene maturacije. Bolesnici koji su imali prethodne tromboze imaju višestruko povišen rizik za nastanak tromboze AVF tokom njene maturacije. Kod bolesnika koji su imali aterosklerotske KVB i ranije tromboze verovatnoća za adekvatnu maturaciju distalne AVF je niža za 68% , odnosno 86%. U našem istraživanju nije utvrđeno postojanje superiornosti antikoagulantne u odnosu na antitrombocitnu profilaksu tj. oba primenjena režima su bila podjednako efikasna. U terminalnoj bubrežnoj insuficijenciji prisutan je značajan poremećaj funkcionalnosti hemostaznog sistema koji se očituje u disfunkciji endotela i poremećenoj (sniženoj) funkcionalnosti trombocita, prisustvu prokoagulantnog stanja koje se manifestuje povišenom trombinskom aktivnošću, povišenom koncentracijom činilaca koagulacije i smanjenom fibrinoliznom aktivnošću. Češća zastupljenost ukupnih ranijih tromboza (arterijskih i venskih), češća zastupljenost izolovanih venskih tromboza i učestalije prisustvo trombofilije prezentovano deficitom PC, prisustvom rezistencije na APC, prisusustvom antifosfolipidnih antikardiolipinskih antitela IgM, heterozigotnog polimorfizma FV G1691A, homozigotne mutacije FII G201210A i niža vrednost agregabilnosti trombocita uz kolagen kao induktor su markeri koji su u našem ispitivanju signifikantno češće zastupljeni kod ispitanika sa trombozom/ afunkcijom AVF za hemodijalizu tokom njenog sazrevanja. Trombofilija je prisutna kod 48.8% bolesnika saTBI, ali našim ispitivanjem nije utvrđen njen uticaj na nastanak rane tromboze/afunkcionalnosti AVF izuzev u grupi bolesnika sa kombinovanom trombofilijom. Mali broj krvarećih komplikacija u našoj studiji ukazuje na bezbednost primenjenog preventivnog režima. Na osnovu dobijenih rezultata može se preporučiti profilaktička primena tiklopidina ili nadroparin-kalcijuma u preventivnim dozama kod bolesnika sa TBI neposredno nakon kreiranja AVF. Primenu profilakse tromboznih komplikacija kod bolesnika sa novokreiranom AVF preporučujemo posebno kod bolesnika koji su imali prethodne tromboze i/ili kliničke manifestacije aterosklerotskih kardiovaskularnih bolesti.</p> / <p>INTRODUCTION: Complications in end stage renal disease (ESRD) when the glomerular filtration rate (GFR) decreases below 10mL/min can only be treated by chronic dialysis or kidney transplant ie. total or partial renal replacement therapy. With prompt education of the patient regarding the progressive course of the chronic kidney disease, possibilities of dialysis treatment and kidney transplantation, the patient should timely be granted permanent functional vascular hemodialysis (HD) access through surgical intervention by creating arteriovenous fistula (AVF), preferably at least 6 months prior to the anticipated start of HD, as period for its maturation is between 4 and 6 weeks. Primary AVF is the generally best recommended permanent vascular access for patients planned for dialysis. The most common reason for dysfunction of the vascular access for hemodialysis are thrombotic complications in 80% of the cases, 90% of which appear in the venous segment of AVF as the consequence of progressive venous neointimal hyperplasia. Beside the histological characteristics of the venous blood vessel wall and hemodynamic conditions, in the etiopathogenesis of this “adaptive answer”, endothel and other components of the hemostatic system (platelet, coagulation and fibrinolysis), immunological and cytological components as well as genetic factors play a very important role. Prevention of occurrence of early thrombosis of vascular access for hemodialysis in patients with ESRD is possible by treatment with antithrombotic drugs, ie. antiplatelet or anticoagulant therapy. OBJECTIVE: Estimate the efficiency of applied antithrombotic drugs (ticlopidine and nadroparincalcium) in prevention of occurrence of early thrombosis/dysfunction of AVF for hemodialysis during its time of maturation within the 6 week period. Examine the level of biomarkers of the hemostatic system and thrombophilic markers in patients with ESRD before the creation of AVF with the goal of finding additional causes of occurrence of early thrombosis/dysfunction of arteriovenous fistula for hemodialysis. Determine the incidence of thrombophilia and its impact on the functionality of AVF and compare the efficiency of applied preventive regimen between patients with and without thrombophilia. MATERIAL AND METHODS: The study included persons of both sexes with previously established diagnosis of ESRD in which there were no contraindications for the planned surgical creation of the first permanent vascular access for hemodialysis in the form of autologous arteriovenous fistula (AAVF). After the surgical creation of the radiocephalic arteriovenous fistula in the distal third of the forearm of the non-dominant hand (89/121), intermedial (4/121) or proximal (28/121) AAVF, the total number of 121 patients were included in the study and divided into three groups in order to estimate the influence of different antithrombotic drugs in prevention of early thrombosis for hemodialysis in patients with ESRD: Group I, control; 40 subjects which did not receive antithrombotic therapy after the creation of AVF, Group II; 42 subjects which started receiving an antithrombotic drug from the tienopiridine group, Ticlodix® (ticlopidine) 2 x ½ of 250mg tbl, daily, during the period of 6 weeks, after the creation of AVF, and Group III; 39 subjects which started subcutaneously receiving a drug from the low-molecular weight herapin group, Fraxiparine® (nadroparine-calcium) 2850 anti Xa i.j. (0.3 ml) daily, during the period of 6 weeks. One-time determination of laboratory parameters and renal function, glucose metabolism and chronic inflammation, hemostatic system functionality, thrombophilic markers and gene polymorphism was performed within two weeks prior to surgical creation of AAVF. The criteria for determining the outcome of the impact of antithrombotic therapy is the maturation of AVF, which is defined as successful if the implementation of effective hemodialysis started at least 6 weeks after its creation, where the effectiveness of hemodialysis is estimated by a competent nephrologist. The diagnosis of the presence of AVF thrombosis was set by a competent vascular surgeon/nephrologist through physical examination during its maturation, which included inspection, palpatory determination of absence of the characteristic thrill and auscultatory characteristics of the flow of AVF, or by ultrasonographic examination by the radiologist. RESULTS: Between the groups in terms of number of thrombosed/dysfunctional AVF during its maturation (12/40 vs. 4/42 vs. 5/39, P = 0.033), a significant statistical difference was established, as well as by comparing the number of thrombosed/dysfunctional AVF during maturation in the control group compared to the group of respondents (unified Group II and Group III) which received antithrombotic prophylaxis (12/40 vs. 9/81, P = 0.009). Through further analysis of the examined groups, a statistically significant difference was observed in the number of thrombosed/dysfunctional AV fistula between the control Group I and Group II (P = 0.019). There was no statistically significant difference noticed in the numbers of thrombosed/dysfunctional AVF between the subjects in the control Group I and Group III, as well as between Group II and Group III. Presence of the number of thrombosed/dysfunctional distal AVF during their maturation (12/33 vs 2/31 vs. 3/24, P = 0.008) between the groups statistically significantly varied, as well as the presence of the number of thrombosed/dysfunctional distal AVF during the maturation in the control group as compared to the group of subjects who received antithrombotic prophylaxis (12/34 vs. 5/55; P=0.002). By testing statistical differences in the number of thrombosed/dysfunctional distal AVF between the subjects in the control Group I and Group II a statistically significant difference (P = 0.005) was established, while there was no statistically significant difference between Group I and Group III (P = 0.051), nor between Group II and Group III (P = 0.439). Among the subgroup of patients with thrombosis/dysfunction of AVF 21/121 (17.35%) and the subgroup of subjects with functionally maturated AVF 90/121 (82.64%), a statistically significant difference of the examined hemostasis parameters was present in the values of platelet aggregation with collagen as the inducer (59.33 ± 75.04 vs. 33.1 ± 29.6; P = 0.033). A significant statistical difference was recorded in the presence of the following thrombophilic markers: deficit of PC (3/21 vs. 3/100; P = 0.030), APC-R (4/21 vs. 5/100; P = 0.026), the presence of antiphospholipid ACL IgM antibodies ( 1/21 vs. 0/100; P = 0.028), heterozygous FV G1691A polymorphism (3/21 vs. 3/100; P = 0.03) and homozygous gene mutation FII G20210A (1/21 vs. 0/100; P = 0.028), between the subgroups of patients with thrombosed/dysfunctional and functional AVF. There also was a significant statistical difference between the groups of patients which encountered thrombosis/dysfunction of AVF and subgroups of subjects with functional maturated AVF in relation to the existence of previous thrombosis (23/21 vs. 19/100; P = 0.000) and the presence of isolated venous thrombosis (9/21 vs. 2/100; P = 0.000). Predictive potential of individual parameters for AVF maturation was tested by univariate logistic regression analysis. During the examination of the influence of individual parameters on fistula maturation, we observed that subjects who received antithrombotic therapy were 3 times more likely to develop functionally maturated AVF [OR 3.45 (1.3-9.03)] as compared to subjects who did not receive any treatment. Subjects which previously had thrombosis had a multiple times increased risk [OR 6.92 (2:51 to 19:06)] of developing thrombosis/dysfunctional AVF during its maturation. When examining the influence of individual parameters on the risk of thrombosis/dysfunction of the distal AVF, we noted that the implementation of antithrombotic therapy [OR 5.4 (CI 1.7 - 17:35)] reduced risk of thrombosis/dysfunction of the distal AVF by five times, ie. that the implementation of antithrombotic therapy increases the chance for adequate distal AVF maturation by five times. The subjects that had atherosclerotic cardiovascular diseases (CVD) [OR 0.32 (0.1-0.98)] or previous thrombosis [OR 0.14 (0.04-00.44)] had a 68% or 86% less chance for adequate distal AVF maturation (334). Thrombophilia was present in 59/121 (48.8%) patients. In relation to the markers of activation of coagulation components of the hemostatic system and inflammatory markers, among subgroups of subjects with or without thrombophilia a statistically significant difference was present in the FVIII concentration (170.35 ± 103.97 vs. 235.26 ± 124.80; P = 0.02) and the platelets/lymphocytes ratio (181 ± 64.58 vs. 148.11 ± 66.15; P = 0.026). In relation to the localization of AVF, in the subgroup of subjects with thrombophilia and thrombosed/dysfunctional AVF, 8/11 of them belonged to distal AVF, 3/11 proximal AVF, while in the subgroup of subjects without thrombophilia and thrombosed/dysfunctional AVF, had 9/10 distal and 1/10 proximal AVF. In the group of subjects with thrombophilia there was no record of the presence of statistically significant differences in the efficiency of antithrombotic regimen which was measured by the frequency of thrombosis/dysfunction of AVF as compared to subjects with thrombophilia which did not receive antithrombotic therapy (5/19 vs. 2/18 vs. 4/22, P = 0.493). In the group of subjects without thrombophilia statistically significant differences were found in the frequency of thrombosis/dysfunctions of AVF among groups with and without the use of antithrombotic drugs in the total number of thrombosed/dysfunctional AVF (7/21 vs. 2/24 vs. 1/17, P = 0.030). Although the presence of thrombosis/dysfunction of AVF in patients with combined thrombophilia was more frequent compared to those who had other types of, or did not have thrombophilia (6/18 vs. 15/103; P = 0.052), it did not reach a statistically significant value. CONCLUSION: Prophylactic use of antithrombotic drugs (ticlopidine and nadroparin-calcium) reduces the incidence of early thrombosis and the occurrence of primary AVF dysfunction for hemodialysis during its maturation. Implementation of antithrombotic therapy reduced risk of thrombosis/ dysfunction of the distal AVF during its maturation by five times. Patients who have had previous thrombosis have multiple times greater risk of AVF thrombosis during its maturation. In patients who had atherosclerotic CVD or previous thrombosis, the probability for adequate maturation of distal AVF is lower by 68% or 86%. In our study there was no evidence of superiority of anticoagulant compared to antiplatelet prophylaxis ie. both regimens were equally effective. In ESRD there is significant disarrangement of hemostatic system functionality, which is reflected in endothelial dysfunction and disturbed (reduced) platelet functionality, the presence of procoagulant condition that is manifested by elevated thrombin activity, increased levels of clotting factors and reduced fibrinolytic activity. More frequent presence of total previous thrombosis (arterial and venous), higher frequency of isolated venous thrombosis and frequent presence of thrombophilia presented by the deficit of PC, the presence of resistance to APC, presence of anticardiolipin antiphospholipid antibodies IgM, heterozygous FV G1691A polymorphism, homozygous mutation FII G201210A and lower value of collagen induced platelet aggregation are the markers in our study which are significantly more frequent in patients with thrombosis/dysfunction of AVF for hemodialysis during its maturation. Thrombophilia is present in 48.8% of patients with ESRD, however our study does not determine its impact on early thrombosis/dysfunction of AVF except in the group of patients with combined thrombophilia. A small number of bleeding complications in our study points to the safety of the applied preventive regimen. Based on the obtained results, prophylactic use of ticlopidine or nadroparin-calcium in preventive doses can be recommended for patients with ESRD immediately after AVF creation. Prophylactic treatment of thrombotic complications in patients with newly created AVF is recommended especially in patients who have had previous thrombosis and/or clinical manifestations of atherosclerotic cardiovascular diseases.</p>
|
35 |
Tratamento endovascular das fístulas carotidocavenosas indiretas / Endovascular treatment of indirect carotid-cavernous fistulasSilva, André Goyanna Pinheiro 27 November 2006 (has links)
As fístulas arteriovenosas da região do seio cavernoso constituem as fístulas carotidocavernosas que podem ser diretas ou indiretas. As indiretas são raras, a sua sintomatologia é variada e o tratamento é controverso. Este estudo compreendeu a análise prospectiva de 44 pacientes portadores de fístulas carotidocavernosas indiretas (FCCI) no período de 01 de janeiro de 1994 e 31 de janeiro de 2004, 42 com etiologia espontânea e dois pacientes com etiologia traumática, sendo estes analisados separadamente. Doze (12) pacientes foram submetidos à conduta expectante e orientados a realizar manobras de compressão carótido-jugular. O tratamento endovascular foi realizado por via arterial, venosa ou combinação dos dois, num total de 30 pacientes. Considerando o grupo inteiro, ocorreu trombose espontânea em aproximadamente 24% dos pacientes. Os sintomas e o aspecto angiográfico após o tratamento evoluíram com melhora ou cura em 100% dos casos, com oclusão completa das FCCI em 63,3%, a grande maioria destes submetidos a apenas um procedimento. Além dos acessos venosos tradicionais aos seios cavernosos, vias de acesso alternativas através da veia oftálmica superior foram realizadas por punção percutânea de veia facial, veia supratroclear ou veia frontal. O material embolizante mais utilizado foi o adesivo tissular líquido, \"cola\", isoladamente ou em conjunto com outros materiais. Houve complicações transitórias em 13,3% dos pacientes tratados e nenhuma complicação permanente foi observada, o que demonstrou a baixa morbidade deste procedimento / The arteriovenous fistulas of the cavernous sinus (CS) region constitute the carotid-cavernous fistula, which can be direct or indirect. The indirect type is quite rare, its clinical features is very inespecific and its treatment modalities controversial. Forty-four patients with indirect carotid-cavernous fistulas (ICCF) were studied in a prospective manner between January 1994 to January 2004, 42 with spontaneous etiology and 2 with traumatic etiology, being these analyzed separately. Twelve (12) patients were submitted to a expectant management and instructed to perform carotid-jugular compression. Endovascular treatment was accomplished by arterial approach, vein approach or combination of both, in a total of 30 patients. Considering the entire group, spontaneous thrombosis was observed in approximately 24%. Symptoms and the angiographic features after endovascular treatment improved or disappeared in 100% of the cases, with total obliteration in 63.3%, most of them submitted to just one procedure. Despite the traditional venous routes to the CS, alternative accesses through the superior ophthalmic vein (SOV) were accomplished by percutaneous puncture of the facial, supratrochlear or frontal vein. Liquid adhesive (glue) was the most often embolic material used isolated or with other materials. No permanent complication was observed and only 13,3% of the patients treated cursed with transitory complications, what demonstrated the low morbidity of this procedure
|
36 |
100 Jahre Schulzahnklinik Zürich /Sigron, Sabrina Lukretia. January 2009 (has links)
Diss. med. dent. Zürich. / Literaturverz.
|
37 |
Modelling the effects of surgical obstetric fistula repairs on the severity of depression and anxiety among women with obstetric fistula in EthiopiaBekele Belayihun Tefera 06 1900 (has links)
Obstetric surgical repair is the common therapeutic intervention available to women with
obstetrical fistula. While surgical repair can address the physical symptoms, it may not end
the psychological challenges that women with fistula face. This longitudinal study
investigated the effects of surgical obstetric fistula repairs on the severity of depression and
anxiety associated with obstetric fistula among 219 women admitted at six fistula hospitals in
Ethiopia. Data was collected through structured Likert-scale questionnaire both on admission
(prior to surgical obstetric fistula repairs) and on discharge (post obstetric fistula repairs)..
Statistical Package for Social Science plus Analysis of Moment Structures (SPSS-AMOS)
version 20 was used for data analysis.
Findings indicate that women with obstetric fistula have higher psychological distress such as
depression (91%) and anxiety (78%) pre-surgical repair than post-surgical repair. These
psychological distresses were exacerbated by poor social and psychological support of
women with obstetric fistula by the family and health care professionals. The findings were
used to develop integrated mental health treatment model for women with obstetric fistula in
order to address psychological health needs of this population. / Health Studies / D. Litt. et Phil. (Health Studies)
|
38 |
Tratamento endovascular das fístulas carotidocavenosas indiretas / Endovascular treatment of indirect carotid-cavernous fistulasAndré Goyanna Pinheiro Silva 27 November 2006 (has links)
As fístulas arteriovenosas da região do seio cavernoso constituem as fístulas carotidocavernosas que podem ser diretas ou indiretas. As indiretas são raras, a sua sintomatologia é variada e o tratamento é controverso. Este estudo compreendeu a análise prospectiva de 44 pacientes portadores de fístulas carotidocavernosas indiretas (FCCI) no período de 01 de janeiro de 1994 e 31 de janeiro de 2004, 42 com etiologia espontânea e dois pacientes com etiologia traumática, sendo estes analisados separadamente. Doze (12) pacientes foram submetidos à conduta expectante e orientados a realizar manobras de compressão carótido-jugular. O tratamento endovascular foi realizado por via arterial, venosa ou combinação dos dois, num total de 30 pacientes. Considerando o grupo inteiro, ocorreu trombose espontânea em aproximadamente 24% dos pacientes. Os sintomas e o aspecto angiográfico após o tratamento evoluíram com melhora ou cura em 100% dos casos, com oclusão completa das FCCI em 63,3%, a grande maioria destes submetidos a apenas um procedimento. Além dos acessos venosos tradicionais aos seios cavernosos, vias de acesso alternativas através da veia oftálmica superior foram realizadas por punção percutânea de veia facial, veia supratroclear ou veia frontal. O material embolizante mais utilizado foi o adesivo tissular líquido, \"cola\", isoladamente ou em conjunto com outros materiais. Houve complicações transitórias em 13,3% dos pacientes tratados e nenhuma complicação permanente foi observada, o que demonstrou a baixa morbidade deste procedimento / The arteriovenous fistulas of the cavernous sinus (CS) region constitute the carotid-cavernous fistula, which can be direct or indirect. The indirect type is quite rare, its clinical features is very inespecific and its treatment modalities controversial. Forty-four patients with indirect carotid-cavernous fistulas (ICCF) were studied in a prospective manner between January 1994 to January 2004, 42 with spontaneous etiology and 2 with traumatic etiology, being these analyzed separately. Twelve (12) patients were submitted to a expectant management and instructed to perform carotid-jugular compression. Endovascular treatment was accomplished by arterial approach, vein approach or combination of both, in a total of 30 patients. Considering the entire group, spontaneous thrombosis was observed in approximately 24%. Symptoms and the angiographic features after endovascular treatment improved or disappeared in 100% of the cases, with total obliteration in 63.3%, most of them submitted to just one procedure. Despite the traditional venous routes to the CS, alternative accesses through the superior ophthalmic vein (SOV) were accomplished by percutaneous puncture of the facial, supratrochlear or frontal vein. Liquid adhesive (glue) was the most often embolic material used isolated or with other materials. No permanent complication was observed and only 13,3% of the patients treated cursed with transitory complications, what demonstrated the low morbidity of this procedure
|
39 |
Estudo retrospectivo da técnica de botoeira em hemodiálise aplicada em usuários do Sistema Único de Saúde (SUS)Silva, Dejanilton Melo da January 2014 (has links)
Submitted by Fabiana Gonçalves Pinto (benf@ndc.uff.br) on 2015-06-18T15:32:47Z
No. of bitstreams: 1
Dejanilton_versão final.pdf: 2073218 bytes, checksum: 30502b09d9c55699b8480f0efd8e0c0c (MD5) / Made available in DSpace on 2015-06-18T15:32:48Z (GMT). No. of bitstreams: 1
Dejanilton_versão final.pdf: 2073218 bytes, checksum: 30502b09d9c55699b8480f0efd8e0c0c (MD5)
Previous issue date: 2014 / A doença renal crônica emerge hoje como um sério problema de saúde pública em todo mundo, sendo considerada uma “epidemia” de crescimento alarmante. Um dos grandes desafios do século XXI será minimizar as implicações promovidas por essa patologia no nível econômico e social. O acesso vascular representa uma das principais causas mobilizadoras de recursos financeiros nas pessoas com insuficiência renal crônica terminal (IRCT). A canulação tradicional em fístula arteriovenosa era, até recentemente, a única prática no serviço de hemodiálise (HD). A partir da introdução de uma alternativa de canulação praticada na Europa e Estados Unidos, se evidenciaram melhorias para o paciente com um protocolo rigoroso que ameniza consideravelmente as complicações com os acessos vasculares definitivos para HD. Estudo descritivo, exploratório e retrospectivo de abordagem quantiqualitativa sobre a técnica de botoeira à pacientes com IRCT, com fístula arteriovenosa pelo Sistema Único de Saúde (SUS), tendo como objetivos: descrever a técnica de botoeira no serviço de hemodiálise; identificar os desfechos da utilização da técnica de botoeira dos pacientes em programa regular de HD durante os últimos três anos; comparar os desfechos obtidos da aplicação da técnica de botoeira em relação à ropeladder e; discutir a técnica de botoeira como indicador de qualidade do cuidado de enfermagem oferecido ao paciente em tratamento hemodialítico usuário do SUS no ambiente de um serviço privado. O cenário foi uma clínica privada conveniada ao SUS localizada na região metropolitana do estado do Rio de Janeiro. A amostra foi constituída por 94 pacientes, e a coleta de dados foi realizada por meio dos prontuários, questionário semiestruturado e entrevista semiestruturada. Do estudo emergiram dados que descrevem a implantação da técnica de botoeira, dados comparativos entre a técnica de botoeira e ropeladder e entrevista sobre a satisfação do uso da técnica de botoeira. Os dados foram analisados utilizando o programa SPSS 17.0, software Bioestat e análise de conteúdo de Bardin. Conclui-se que a técnica de botoeira demonstrou-se benéfica ao paciente em terapia hemodialítica em todos os aspectos, com ênfase nos aspectos de dor, autoimagem e autoestima. Permitiu observar, também, que os gastos dos cofres públicos com acesso vascular definitivo foram diminuídos e será necessária a divulgação deste estudo no âmbito nacional e internacional para disseminação da informação. Ressalta-se a importância de novos estudos para criação e validação de um protocolo que seja viável na utilização da técnica de botoeira aos pacientes submetidos à terapia hemodialítica no Brasil. / Chronic kidney disease emerges today as a serious public health problem worldwide and is considered an "epidemic" of alarming growth. One of the great challenges of the 21st century will minimize the implications promoted by this pathology in the economic and social level. The vascular access is one of the main causes of mobilizing financial resources in people with chronic kidney disease (CKD). The traditional cannulation in arteriovenous fistula was, until recently, the only practical in hemodialysis (HD) services. From the introduction of an alternative cannulation practiced in Europe and the United States, noted improvements for the patient with a strict protocol that greatly eases the complications with the definitive vascular access for HD. Descriptive, exploratory and retrospective study of quantiqualitative approach about the buttonhole technique to CKD patients with arteriovenous fistula by the Unified Health System (UHS), having as objectives: to describe the buttonhole technique in HD services; identify the outcomes of using the buttonhole technique of the patients in a HD regular program during the last three years; compare outcomes obtained from the application of the buttonhole technique in relation to ropeladder and; discuss the buttonhole technique as a quality indicator of the nursing care provided to patients in UHS HD user treatment in a private service. The study setting was a private clinic contracted to UHS located in the metropolitan region of the state of Rio de Janeiro. The sample consisted of 94 patients, and data collection was performed by means of the medical records, semi-structured questionnaire and semi-structured interview. Emerged data describing the implementation of the buttonhole technique, comparative data between the buttonhole technique and ropeladder and interview on satisfaction of using the buttonhole technique. Data were analyzed using SPSS 17.0 software and Bioestat and content analysis by Bardin. It concludes that the buttonhole technique proved to be beneficial to the patient in hemodialysis in all aspects, with emphasis on aspects of pain, self-image and self-esteem. Was observed that the expenditure of public funds with definitive vascular access were decreased and will require the disclosure of this study in the national and international level for dissemination of information. We emphasize the importance of new studies for the development and validation of a protocol that is viable in the use of the buttonhole technique for patients undergoing HD in Brazil.
|
40 |
The Vicious Circle of Health Security: Vaginal Fistula in Conflict Settings and its Interdependency with Female OppressionMetelmann, Isabella B., Busemann, Alexandra 02 November 2023 (has links)
The complex and multilayered interdependence of health and security gets exceedingly obvious in conflict-related sexual violence (CRSV); however, its scientific study is exceptionally invisible. Political unrest increases incidence of gender-based violence (GBV). Rapes, including gang rapes, and forced insertion into the female genitalia of foreign bodies such as bottles, sticks, and weapons can lead to injury of the vagina and the development of traumatic vaginal fistulas (TVF). This paper aims to give structure to the particular characteristics of traumatic vaginal fistula in conflict settings and its immanent linkage to human security. The authors reviewed all papers concerning prevalence and causes of CRSV-caused TVF (CRSV-TVF) that were available on PubMed and GoogleScholar in February 2021. Findings were integrated into feminist theory on CRSV to identify the connecting linkages of security, health, and gender equality. CRSV-caused TVF illustrate well the complex interdependences of health and security: (1) insecurity leads to a higher prevalence of sexual violence; (2) sexual violence can serve as a weapon of war; (3) insecurity prolongs sufficient medical care; (4) vaginal fistula impede female empowerment and societal development. The multiple threads of their connection reveal several implications for the prevention and treatment of TVF. The reciprocal connection of CRSV and security exemplifies a vicious circle of health security.
|
Page generated in 0.0545 seconds